A sequential erythropoietin and GM-CSF schedule offers clinical benefits in the treatment of anaemia in myelodysplastic syndromes-Reference-Cited by-同舟云学术

A sequential erythropoietin and GM-CSF schedule offers clinical benefits in the treatment of anaemia in myelodysplastic syndromes

Published:1996-08 Issue:8 Volume:20 Page:693-699
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Bernell Per,Stenke Lelf,Wallvik Jonas,Hippe Erik,Hast Robert

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference20 articles.

1. Therapeutic aspects on myelodysplastic syndromes in chronic phase;Hast;Leukemia Res.,1992

2. High-dose recombinant human erythropoietin for treatment of anaemia in myelodysplastic syndromes and paroxysmal noctural hemoglobinuria: a pilot study;Stebler;Expl Hematol.,1990

3. Response to recombinant human erythropoietin treatment in myelodysplastic syndromes (MDS);Hast;J. Int. Med.,1991

4. Treatment of myelodysplastic syndromes with recombinant human erythropoietin;Hellström;Eur. J. Haematol.,1991

5. Erythropoietin treatment in patients with myelodysplastic syndrome and anemia;Kurzrock;Leukemia,1991

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of granulocyte colony stimulating factor in combination with erythropoiesis stimulating agents for treatment of anemia in patients with lower risk myelodysplastic syndromes: A systematic review;Critical Reviews in Oncology/Hematology;2019-04

2. Supportive care in myelodysplastic syndromes: hemopoietic cytokine and iron chelation therapy;Myelodysplastic Syndromes;2005-11-10

3. Hematopoietic Growth Factor Therapy for Myelodysplastic Syndromes and Aplastic Anemia;Hematopoietic Growth Factors in Oncology;2004

4. Recombinant human erythropoietin in combined treatment with granulocyte- or granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes;Journal of Cancer Research and Clinical Oncology;2002-09-01

5. Serum erythropoietin (EPO) levels correlate with survival and independently predict response to EPO treatment in patients with myelodysplastic syndromes;European Journal of Haematology;2002-03